# Anti-Adalimumab Antibodies Purified from Juvenile Idiopathic Arthritis Patients: Kinetic Characterization Among Biosimilars

## TL;DR

This study compares how antibodies from arthritis patients interact with adalimumab and its biosimilars, finding similar binding strengths across all formulations.

## Contribution

The study provides kinetic characterization of anti-adalimumab antibodies in JIA patients across biosimilars and the originator.

## Key findings

- Purified AAA showed comparable KD values across Humira®, Hyrimoz®, and Imraldi®.
- Affinity for all formulations was in the range of 10−9 M > KD > 10−10 M.
- Variations were more patient-specific than biosimilar-specific.

## Abstract

The use of adalimumab biosimilars has become increasingly common in clinical practice, reflecting their growing acceptance and efficacy as therapeutic alternatives to reference biologics. However, studies investigating the molecular interactions between anti-adalimumab antibodies (AAA) elicited in patients and different adalimumab biosimilars remain limited. This study aims to characterize the kinetic interactions between purified AAA from pediatric patients with Juvenile Idiopathic Arthritis and three adalimumab formulations: the originator Humira®, and the biosimilars GP2017 (Hyrimoz®) and SB5 (Imraldi®). For this purpose, adalimumab formulations were immobilized on a gold chip, and purified AAA were flowed to perform further kinetic analysis using the surface plasmon resonance (SPR) technology. Results showed that the KD values for purified AAA from patients treated with biosimilars GP2017 (Hyrimoz®) or SB5 (Imraldi®) were comparable across all formulations tested, including the originator Humira®. AAA interacted with Humira®, Hyrimoz®, and Imraldi® with similar apparent affinity (10−9 M > KD > 10−10 M); slight variations have been observed among patients, less among biosimilars. The similarity in KD values across biosimilars and the originator supports the notion that, at the level of immunogenicity, biosimilars can be considered clinically comparable to the originator.